Agenus Inc  

(Public, NASDAQ:AGEN)   Watch this stock  
Find more results for AGEN
-0.13 (-2.53%)
Real-time:   10:34AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.11 - 5.35
52 week 2.27 - 6.49
Open 5.25
Vol / Avg. 210,503.00/3.37M
Mkt cap 321.37M
P/E     -
Div/yield     -
EPS -0.45
Shares 62.68M
Beta 1.72
Inst. own 46%
Feb 9, 2015
Agenus Inc at Biotechnology Industry Organization CEO & Investor Conference - 4:30PM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -518.71% -987.54%
Operating margin -490.73% -820.31%
EBITD margin - -801.05%
Return on average assets -34.64% -94.08%
Return on average equity -61.47% -
Employees 114 -
CDP Score - -


NEW YORK, NY 10010
United States - Map
+1-212-9948200 (Phone)
+1-781-6744200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Agenus Inc., including its subsidiaries, (Agenus) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases. The Company's core technology portfolio consists of its Saponin Platform (based on its saponin adjuvant based technologies) and its Heat Shock Protein (HSP) Platform (based on its HSP based technologies). The Company's key candidates from these technology platforms include QS-21 Stimulon adjuvant (QS-21), the Prophage Series vaccines and HerpV. The Company's products and technologies under development include QS-21. A number of pharmaceutical and biotechnology companies have licensed QS-21 from the Company for use in vaccines to treat a wide variety of human diseases. The Company has retained worldwide manufacturing rights for QS-21. In February 2014, Agenus Inc. completed the acquisition of 4-Antibody AG.

Officers and directors

Garo H. Armen Ph.D. Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Christine M. Klaskin Principal Financial Officer, Principal Accounting Officer, Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Robert B. Stein M.D., Ph.D. Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Karen H. Valentine Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Ozer Baysal Chief Business Officer
Age: 58
Bio & Compensation  - Reuters
Timothy R. Wright Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
Shalini Sharp Director
Age: 39
Bio & Compensation  - Reuters
Brian Corvese Independent Director
Age: 56
Bio & Compensation  - Reuters
Tom Dechaene Independent Director
Age: 55
Bio & Compensation  - Reuters
Wadih Jordan Independent Director
Age: 79
Bio & Compensation  - Reuters